Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer.

MLA

Sehgal, Kartik, et al. “Association of Extended Dosing Intervals or Delays in Pembrolizumab-Based Regimens With Survival Outcomes in Advanced Non–small-Cell Lung Cancer.” Clinical Lung Cancer, vol. 22, no. 3, May 2021, pp. e379–89. EBSCOhost, https://doi.org/10.1016/j.cllc.2020.05.028.

APA

Sehgal, K., Bulumulle, A., Brody, H., Gill, R. R., Macherla, S., Qilleri, A., McDonald, D. C., Cherry, C. R., Shea, M., Huberman, M. S., VanderLaan, P. A., Weiss, G. J., Walker, P. R., Costa, D. B., & Rangachari, D. (2021). Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer. Clinical Lung Cancer, 22(3), e379–e389. https://doi.org/10.1016/j.cllc.2020.05.028

Chicago

Sehgal, Kartik, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, et al. 2021. “Association of Extended Dosing Intervals or Delays in Pembrolizumab-Based Regimens With Survival Outcomes in Advanced Non–small-Cell Lung Cancer.” Clinical Lung Cancer 22 (3): e379–89. doi:10.1016/j.cllc.2020.05.028.